Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Incyte Biosciences Luxembourg

M&A STATUS
101-200 EMPLOYEES
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Manufacturer of drugs for cancer treatment. The division is based in Europe and is engaged in manufacturing and marketing of the drug ponatinib (Iclusig). The drug is used for treatment of blood cancers.

Formerly Known As
Ariad Pharmaceuticals (Luxembourg)
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Acquirer
Primary Office
  • Route de la Corniche 1
  • Epalinges
  • 1066 Lausanne
  • Switzerland

Incyte Biosciences Luxembourg Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Incyte Biosciences Luxembourg‘s full profile, request access.

Request full access to PitchBook

Incyte Biosciences Luxembourg Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Incyte Biosciences Luxembourg‘s full profile, request access.

Request full access to PitchBook